NASDAQ:ELDN

Eledon Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ELDN

*Your capital is at risk

$3.81

-0.110 (-2.81%)

At Close: Jun 22, 2026

Eledon Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 48.88M and sold 0 ELDN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	48.88M shares
● Sell	0 shares
100% Buy Activity Weak Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 10, 2035 Buy	Stock Option (right to buy) A-Award	Robinson James A. Jr. Director	Director	30 870 Value: $124.7K
Jan 10, 2035 Buy	Stock Option (right to buy) A-Award	Robinson James A. Jr. Director	Director	30 870 Value: $124.7K
Jan 10, 2026 Buy	Restricted Stock Units M-Exempt	Robinson James A. Jr. Director	Director	3 430 Value: $13.1K
Jan 10, 2026 Buy	Common Stock M-Exempt	Robinson James A. Jr. Director	Director	3 430 Value: $13.1K
Jan 10, 2026 Buy	Common Stock M-Exempt	Mcbride John S. Director	Director	3 430 Value: $13.1K
Jan 10, 2026 Buy	Restricted Stock Units M-Exempt	Mcbride John S. Director	Director	3 430 Value: $13.1K
Jan 10, 2026 Buy	Common Stock M-Exempt	Hillson Jan Director	Director	3 430 Value: $13.1K
Jan 10, 2026 Buy	Restricted Stock Units M-Exempt	Hillson Jan Director	Director	3 430 Value: $13.1K
Jan 10, 2026 Buy	Common Stock M-Exempt	Kirk Allan Director	Director	3 430 Value: $13.1K
Jan 10, 2026 Buy	Restricted Stock Units M-Exempt	Kirk Allan Director	Director	3 430 Value: $13.1K
Jan 10, 2026 Buy	Common Stock M-Exempt	Katkin Keith Director	Director	8 575 Value: $32.7K
Jan 10, 2026 Buy	Restricted Stock Units M-Exempt	Katkin Keith Director	Director	8 575 Value: $32.7K
Jan 10, 2026 Buy	Common Stock M-Exempt	Lee June Director	Director	3 430 Value: $13.1K
Jan 10, 2026 Buy	Restricted Stock Units M-Exempt	Lee June Director	Director	3 430 Value: $13.1K
Jan 10, 2025 Buy	Stock Option (right to buy) A-Award	Hillson Jan Director	Director	30 870 Value: $124.7K
Jan 10, 2025 Buy	Restricted Stock Units A-Award	Hillson Jan Director	Director	3 430 Value: $13.9K
Jan 10, 2025 Buy	Stock Option (right to buy) A-Award	Mcbride John S. Director	Director	30 870 Value: $124.7K
Jan 10, 2025 Buy	Restricted Stock Units A-Award	Mcbride John S. Director	Director	3 430 Value: $13.9K
Jan 10, 2025 Buy	Stock Option (right to buy) A-Award	Gros David-alexandre C Chief Executive Officer	CEO / President	600 000 Value: $2.42M
Jan 10, 2025 Buy	Restricted Stock Units A-Award	Gros David-alexandre C Chief Executive Officer	CEO / President	66 500 Value: $268.7K
Jan 10, 2025 Buy	Stock Option (right to buy) A-Award	Little Paul Sean Chief Financial Officer	C-Suite Officer	175 000 Value: $707.0K
Jan 10, 2025 Buy	Restricted Stock Units A-Award	Little Paul Sean Chief Financial Officer	C-Suite Officer	75 000 Value: $303.0K
Jan 10, 2025 Buy	Stock Option (right to buy) A-Award	Katkin Keith Director	Director	77 175 Value: $311.8K
Jan 10, 2025 Buy	Restricted Stock Units A-Award	Katkin Keith Director	Director	8 575 Value: $34.6K
Jan 10, 2025 Buy	Stock Option (right to buy) A-Award	Perrin Steven President	CEO / President	243 000 Value: $981.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ELEDON PHARMACEUTICALS, INC.

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical tri...

Read Full Profile Here